ID

13071

Beschreibung

Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00193531

Link

https://clinicaltrials.gov/show/NCT00193531

Stichworte

  1. 14.01.16 14.01.16 -
Rechteinhaber

CC BY-NC 3.0

Hochgeladen am

14. Januar 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Neuroendocrine Carcinoma NCT00193531

Eligibility Neuroendocrine Carcinoma NCT00193531

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
metastatic poorly differentiated neuroendocrine carcinoma
Beschreibung

neuroendocrine carcinoma

Datentyp

boolean

Alias
UMLS CUI [1]
C0206695
unknown primary site
Beschreibung

primary site

Datentyp

boolean

Alias
UMLS CUI [1]
C0475447
able to perform activities of daily living with minimal assistance
Beschreibung

activities of daily living

Datentyp

boolean

Alias
UMLS CUI [1]
C0001288
measurable or evaluable disease
Beschreibung

measurable disease

Datentyp

boolean

Alias
UMLS CUI [1]
C1513041
adequate bone marrow, liver functions and kidney function
Beschreibung

adequate bone marrow, liver functions and kidney function

Datentyp

boolean

Alias
UMLS CUI [1]
C0678852
no previous treatment with chemotherapy
Beschreibung

chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0392920
understand the nature of this study and give written informed consent.
Beschreibung

informed consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
age < 18 years
Beschreibung

age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
previous malignancy within five years
Beschreibung

malignancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0006826
women pregnant or lactating
Beschreibung

pregnancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
recent history of cardiovascular disease
Beschreibung

cardiac disease

Datentyp

boolean

Alias
UMLS CUI [1]
C0018799
meningeal metastases
Beschreibung

meningeal metastases

Datentyp

boolean

Alias
UMLS CUI [1]
C0220654

Ähnliche Modelle

Eligibility Neuroendocrine Carcinoma NCT00193531

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
neuroendocrine carcinoma
Item
metastatic poorly differentiated neuroendocrine carcinoma
boolean
C0206695 (UMLS CUI [1])
primary site
Item
unknown primary site
boolean
C0475447 (UMLS CUI [1])
activities of daily living
Item
able to perform activities of daily living with minimal assistance
boolean
C0001288 (UMLS CUI [1])
measurable disease
Item
measurable or evaluable disease
boolean
C1513041 (UMLS CUI [1])
adequate bone marrow, liver functions and kidney function
Item
adequate bone marrow, liver functions and kidney function
boolean
C0678852 (UMLS CUI [1])
chemotherapy
Item
no previous treatment with chemotherapy
boolean
C0392920 (UMLS CUI [1])
informed consent
Item
understand the nature of this study and give written informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
age
Item
age < 18 years
boolean
C0001779 (UMLS CUI [1])
malignancy
Item
previous malignancy within five years
boolean
C0006826 (UMLS CUI [1])
pregnancy
Item
women pregnant or lactating
boolean
C0032961 (UMLS CUI [1])
cardiac disease
Item
recent history of cardiovascular disease
boolean
C0018799 (UMLS CUI [1])
meningeal metastases
Item
meningeal metastases
boolean
C0220654 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video